Pharmacologic treatment of behavioural disturbances in Autism spectrum disorders: A review;Traitement pharmacologique des comportements problématiques associés aux troubles du spectre autistique: Revue de la littérature

Neuropsychiatrie de l'Enfance et de l'Adolescence

Volumn 60, Issue 1, 2012, Pages 42-51

  Perisse D ^a   Guinchat, V ^a   Hellings, J A ^b   Baghdadli, A ^c  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^c Montpellier 1 University   (France)

Author keywords

Anti epileptics; Antipsychotics; Autism spectrum disorders; Behavioral disturbances; Psychopharmacology; Psychostimulants; Serotonin reuptake inhibitors

Indexed keywords

ANTICONVULSIVE AGENT; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; MELATONIN; PSYCHOSTIMULANT AGENT; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR;

ATTENTION DEFICIT DISORDER; AUTISM; BEHAVIOR DISORDER; CHILD BEHAVIOR; COMPULSION; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; ENVIRONMENTAL FACTOR; HUMAN; HYPERACTIVITY; PATIENT EDUCATION; PRESCRIPTION; PSYCHOLOGIC ASSESSMENT; RISK BENEFIT ANALYSIS; SHORT SURVEY; SLEEP DISORDER; SYMPTOM; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 84856801547     PISSN: 02229617     EISSN: 17696615     Source Type: Journal    
DOI: 10.1016/j.neurenf.2011.10.011     Document Type: Short Survey

References (43)

1. Baghdadli A., Gonnier V., Aussilloux C. Review of psychopharmacological treatments in adolescents and adults with autistic disorders. Encephale 2002, 28(3Pt 1):248-254.
2. Aman M.G., Lam K.S.L., Van Bourgondien M.E. Medication patterns in patients with autism: temporal, regional, and demographic influences. J Child Adolesc Psychopharmacol 2005, 15(1):116-126.
3. Périsse D., et al. Risk factors of acute behavioral regression in psychiatrically hospitalized adolescents with autism. J Can Acad Child Adolesc Psychiatry 2010, 19(2):100-108.
4. Canitano R., Scandurra V. Psychopharmacology in autism: an update. Prog Neuropsychopharmacol Biol Psychiatry 2011, 35(1):18-28.
5. Lubetsky M.J., Handen B.L. Medication treatment in autism spectrum disorder. Speaker's Journal 2008, 8(2003):97-107.
6. Williams K., Dm W., Silove N., Hazell P. Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD) (Review). Child Dev 2010, 9:1-33.
7. Rossignol D.A. Novel and emerging treatments for autism spectrum disorders: a systematic review. Ann Clin Psychiatry 2009, 21(4):213-236.
8. Huffman L.C., Sutcliffe T.L., Tanner I.S.D., Feldman H.M. Management of symptoms in children with autism spectrum disorders: a comprehensive review of pharmacologic and complementary-alternative medicine treatments. J Dev Behav Pediatr 2011, 32(1):56-68.
9. McDougle C.J., Stigler K.A., Erickson C.A., Posey D.J. Atypical antipsychotics in children and adolescents with autistic and other pervasive developmental disorders. J Clin Psychiatry 2008, 69(Suppl. 4, 4):15-20.
10. McPheeters M.L., et al. A systematic review of medical treatments for children with autism spectrum disorders. Pediatrics 2011, 127(5):e1312-e1321.
11. Zaidman-Zait A., et al. Factor analysis of the Parenting Stress Index-Short Form with parents of young children with autism spectrum disorders. Autism Res 2011, 4(5):336-346.
12. Ruppan (Research Units on Pediatric Psychopharmacology Autism Network) Risperidone in children with autism and serious behavioral problems. N Engl J Med 2002, 347(5):314-321.
13. Miral S., Gencer O., Inal-Emiroglu F.N., Baykara B., Baykara A., Dirik E. Risperidone versus haloperidol in children and adolescents with AD: a randomized, controlled, double-blind trial. Eur Child Adolesc Psychiatry 2008, 17(1):1-8.
14. Nagaraj R., Singhi P., Malhi P. Risperidone in children with autism: randomized, placebo-controlled, double-blind study. J Child Neurol 2006, 21(6):450-455.
15. Luby J., et al. Risperidone in preschool children with autistic spectrum disorders: an investigation of safety and efficacy. J Child Adolesc Psychopharmacol 2006, 16(5):575-587.
16. Shea S., et al. Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics 2004, 114(5):e634-e641.
17. Hollander E., et al. A double-blind placebo-controlled pilot study of olanzapine in childhood/adolescent pervasive developmental disorder. J Child Adolesc Psychopharmacol 2006, 16(5):541-548.
18. Marcus R.N., et al. A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. J Am Acad Child Adolesc Psychiatry 2009, 48(11):1110-1119.
19. Owen R., et al. Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Pediatrics 2009, 124(6):1533-1540.
20. Rojahn J., Aman M.G., Matson J.L., Mayville E. The Aberrant Behavior Checklist and the Behavior Problems Inventory: convergent and divergent validity. Res Dev Disabil 2003, 24(5):391-404.
21. Hollander E., et al. A placebo controlled crossover trial of liquid fluoxetine on repetitive behaviors in childhood and adolescent autism. Neuropsychopharmacology 2005, 30(3):582-589.
22. McDougle C.J., Naylor S.T., Cohen D.J., Volkmar F.R., Heninger G.R., Price L.H. A double-blind, placebo-controlled study of fluvoxamine in adults with autistic disorder. Arch Gen Psychiatry 1996, 53(11):1001-1008.
23. King B.H., et al. Lack of efficacy of citalopram in children with autism spectrum disorders and high levels of repetitive behavior: citalopram ineffective in children with autism. Arch Gen Psychiatry 2009, 66(6):583-590.
24. Ruppan (Research Units on Pediatric Psychopharmacology Autism Network) Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity. Arch Gen Psychiatry 2005, 62(11):1266-1274.
25. Ghuman J.K., et al. Randomized, placebo-controlled, crossover study of methylphenidate for attention-deficit/hyperactivity disorder symptoms in preschoolers with developmental disorders. Journal Child Adolesc Psychopharmacol 2009, 19(4):329-339.
26. Handen B.L., Johnson C.R., Lubetsky M. Efficacy of methylphenidate among children with autism and symptoms of attention-deficit hyperactivity disorder. J Autism Dev Disord 2000, 30(3):245-255.
27. Arnold L.E., et al. Atomoxetine for hyperactivity in autism spectrum disorders: placebo-controlled crossover pilot trial. J Am Acad Child Adolesc Psychiatry 2006, 45(10):1196-1205.
28. Hollander E., Soorya L., Wasserman S., Esposito K., Chaplin W., Anagnostou E. Divalproex sodium vs. placebo in the treatment of repetitive behaviours in autism spectrum disorder. Int J Neuropsychopharmacol 2006, 9(2):209-213.
29. Hollander E., et al. Divalproex sodium vs placebo for the treatment of irritability in children and adolescents with autism spectrum disorders. Neuropsychopharmacology 2010, 35(4):990-998.
30. Hellings J.A., et al. A double-blind, placebo-controlled study of valproate for aggression in youth with pervasive developmental disorders. J Child Adolesc Psychopharmacol 2005, 15(4):682-692.
31. Belsito K.M., Law P.A., Kirk K.S., Landa R.J., Zimmerman A.W. Lamotrigine therapy for autistic disorder: a randomized, double-blind, placebo-controlled trial. J Autism Dev Disord 2001, 31(2):175-181.
32. Wasserman S., et al. Levetiracetam versus placebo in childhood and adolescent autism: a double-blind placebo-controlled study. Int Clin Psychopharmacol 2006, 21(6):63-67.
33. Reynolds A.M., Malow B.A. Sleep and autism spectrum disorders. Pediatr Clin North Am 2011, 58(3):685-698.
34. Wasdell M.B., et al. A randomized, placebo-controlled trial of controlled release melatonin treatment of delayed sleep phase syndrome and impaired sleep maintenance in children with neurodevelopmental disabilities. J Pineal Res 2008, 44(1):57-64.
35. Wright B., et al. Melatonin versus placebo in children with autism spectrum conditions and severe sleep problems not amenable to behaviour management strategies: a randomised controlled crossover trial. J Autism Dev Disord 2011, 41(2):175-184.
36. Rezaei V., et al. Double-blind, placebo-controlled trial of risperidone plus topiramate in children with autistic disorder. Prog Neuropsychopharmacol Biol Psychiatry 2010, 34(7):1269-1272.
37. Akhondzadeh S., et al. A double-blind placebo controlled trial of piracetam added to risperidone in patients with autistic disorder. Child Psychiatry Hum Dev 2008, 39(3):237-245.
38. Akhondzadeh S., et al. Double-blind placebo-controlled trial of pentoxifylline added to risperidone: effects on aberrant behavior in children with autism. Prog Neuropsychopharmacol Biol Psychiatry 2010, 34(1):32-36.
39. King B.H., et al. Double-blind, placebo-controlled study of amantadine hydrochloride in the treatment of children with autistic disorder. J Am Acad Child Adolesc Psychiatry 2001, 40(6):658-665.
40. Campbell M., Anderson L.T., Small A.M., Locascio J.J., Lynch N.S., Choroco M.C. Naltrexone in autistic children: a double-blind and placebo-controlled study. Psychopharmacol Bull 1990, 26(1):130-135.
41. Bouvard M.P., et al. Low-dose naltrexone effects on plasma chemistries and clinical symptoms in autism: a double-blind, placebo-controlled study. Psychiatry Res 1995, 58(3):191-201.
42. Willemsen-Swinkels S.H., Buitelaar J.K., Nijhof G.J., van England H. Failure of naltrexone hydrochloride to reduce self-injurious and autistic behavior in mentally retarded adults. Double-blind placebo-controlled studies. Arch Gen Psychiatry 1995, 52(9):766-773.
43. Esbensen A.J., Greenberg J.S., Seltzer M.M., Aman M.G. A longitudinal investigation of psychotropic and non-psychotropic medication use among adolescents and adults with autism spectrum disorders. J Autism Dev Disord 2009, 39(9):1339-1349.